Antisense Efficacy

Site-Restricted In Vivo and Ex Vivo Models
  • Leonard M. Neckers
  • Daniel Geselowitz
  • Christine Chavany
  • Luke Whitesell
  • Raymond Bergan
Part of the Methods in Molecular Medicine book series (MIMM, volume 1)


In the laboratory, antisense oligodeoxynucleotides (ODN) have repeatedly demonstrated efficacy in modulating the expression of various genes, thus providing important insights into their roles in tumorigenesis or normal growth and development (1, 2, 3). Although attention has been focused recently on the development of antisense ODN as therapeutics for a variety of diseases, including cancer (4), systemic application of ODN to treat tumors other than those of the hematopoietic system presents several problems, not least of which is the ability of systemically administered antisense to reach distant tumor sites. This is particularly true when considering tumors of the central nervous system (CNS), such as glioblastomas and HIV-associated B-cell lymphomas. In this case, the blood-brain barrrer poses an additional obstacle to successful delivery of anionic ODN. On the other hand, the intractability of CNS tumors to standard chemotherapy makes them interesting candidates for antisense intervention. The first model system we will discuss mvolves direct mfusron of ODN into the CNS for the purpose of continuous perfusion of tumor cells.


Primary Central Nervous System Lymphoma Central Nervous System Tumor Central Nervous System Prophylaxis Antisense Effect Fluorescein Label 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Cohen, J S (1991) Chemically modified oligodeoxynucleotide analogs as regulators of viral and cellular gene expression, in Gene Regulation. Biology of Antisense RNA and DNA (Erickson, R. P. and Izant, J. G., eds.), Raven, New York, pp. 247–260.Google Scholar
  2. 2.
    Goodchtld, J. (1989) Inhibition of gene expression by oligonucleotides, in Oligodeoxynucleotides Antisense Inhibitors of Gene Expression (Cohen, J. S, ed), Macmillan, London, pp 53–77.Google Scholar
  3. 3.
    Neckers, L., Whitesell, L, Rosolen, A., and Geselowitz, D. A. (1992) Antisense inhibition of oncogene expression. CRC Crit. Rev Oncogenesis 3, 175–231.Google Scholar
  4. 4.
    Zamecnik, P C (1991) Oligonucleotide based hybridization as a modulator of genetic message readout, in Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS (Wickstrom, E., ed.), Wiley-Liss, New York, pp. 1–6.Google Scholar
  5. 5.
    Neckers, L.M. (1993) Cellular Internalization of oligodeoxynucleotides, in Antisense Research and Appllcations (Crooke, S. T. and Lebleu, B, eds.), CRC, Boca Raton, FL, pp. 451–460.Google Scholar
  6. 6.
    Whitesell, L., Rosolen, A., and Neckers, L M (1991) In vivo modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide Antisense Res Dev 1, 343–350.PubMedGoogle Scholar
  7. 7.
    Srmons, M., Edelman, E. R., DeKeyser, J.-L., Langer, R, and Rosenberg, R. D (1992) Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo Nature 359, 67–70.CrossRefGoogle Scholar
  8. 8.
    Whttesell, L, Geselowitz, D., Chavany, C., Fahmy, B., Walbndge, S, Alger, J.R., and Neckers, L M (1993) Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides implications for therapeutic application within the central nervous system. Proc. Natl Acad SCi USA 90, 4665–4669CrossRefGoogle Scholar
  9. 9.
    Bass, N and Lundborg, P (1973) Postnatal development of bulk flow in the cerebrospinal fluid system of the albino rat clearance of carboxyl-(14C)inulin after intrathecal infusion Brain Res 52, 323–332.PubMedCrossRefGoogle Scholar
  10. 10.
    Agrawal, S, Temsamam, J, and Tang, Y T. (1991) Pharmacokmettcs, bio-distribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Set USA 88, 7595–7599.CrossRefGoogle Scholar
  11. 11.
    Poplack, D. G and Riccardi, R (1987) The role of pharmacology in pediatric oncology, in The Role of Pharmacology in Pediatrie Oncology (Poplack, D G., Massimo, L, and Cornagha-Ferraris, P., eds.), Martinus Nijhoff, Boston, pp 137–156.Google Scholar
  12. 12.
    Blaney, S. M., Balis, F.M., and Poplack, D. G. (1991) Pharmacologic approaches to the treatment of meningeal malignancy. Oncology 5, 107–116.PubMedGoogle Scholar
  13. 13.
    Machado, M, Salcman, M, Kaplan, R.S, and Montgomery, E (1985) Expanded role of the cerebrospinal fluid reservoir in neurooncology: indications, causes of revision, and complications. Neurosurgery 17, 600–603PubMedCrossRefGoogle Scholar
  14. 14.
    Sundaresan, N and Suite, N. D. A (1989) Optimal use of the omaya reservoir in clinical oncology. Oncology 3, 15–22PubMedGoogle Scholar
  15. 15.
    Urch, C, George, A, Stevenson, G, Bolognesi, A, Stirpe, F, Weller, R, and Glennie, M (1991) Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin Int J Cancer 47, 909–915PubMedCrossRefGoogle Scholar
  16. 16.
    Moseley, R P., Papanastassiou, V, Zalutsky, M R, Ashpole, R. D., Evans, S., Bigner, D.D, and Kemshead, J.T. (1992) Immunoreactivny, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. Int J Cancer 52, 38–43PubMedCrossRefGoogle Scholar
  17. 17.
    List, J., Moser, R. P., Steuer, M., Loudon, W. G, Blacklock, J. B, and Grimm, E. A(1992) Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis rapid induction of tumor necrosts factor alpha, interleukin 1 beta, interleukin 6, gamma-Interferon, and soluble mterleukin 2 receptor (M, 55,000 protein). Cancer Res 52, 1123–1128PubMedGoogle Scholar
  18. 18.
    Pluda, J. M., Yarchoan, R, Jaffe, E. S, Feurstem, I. M., Solomon, D., Steinberg, S M, Wyvill, M., Raubnschek, A, Katz, D, and Broder, S. (1990) Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on longterm antiretroviral therapy Ann Intern Med 113, 276–282.PubMedGoogle Scholar
  19. 19.
    McCarthy, M M., Brooks, P. J., Pfaus, J. G., Brown, H. E., Flanagan, L. M., Schwartz-Giblin, S., and Pfaff, D W (1993) Antisense oligodeoxynucleotides in behavioral neuroscience. Neuroprotocols 2, 64–66.CrossRefGoogle Scholar
  20. 20.
    La Rocca, R.V, Rosenblum, M, Westermark, B., and Israel, M. A (1989) Patterns of protooncogene expression in human glioma cell lines J Neurosci Res 24, 97–106.CrossRefGoogle Scholar
  21. 21.
    Morrison, R.S. (1991) Suppression of basrc tibroblast growth factor expression by antisense oligodeoxynucleotides inhabits the growth of transformed human astrocytes J Biol Chem 266, 728–734.PubMedGoogle Scholar
  22. 22.
    Bergan, R, Connell, Y, Fahmy, B, and Neckers, L M (1993) Electroporatron enhances c-myc antrsense ohgodeoxynucleotide efficacy Nucleic Acids Res 21, 3567–3573PubMedCrossRefGoogle Scholar
  23. 23.
    McManaway, M E, Neckers, L M, Loke, S L, Al-Nasser, A A, Redner, R L, Shiramizu, B T, Goldschmidts, W L, Huber, B E., Bhatra, K., and Magrath, I T (1990) Tumor-specific inhrbition of lymphoma growth by an antisense ohgodeoxynucleotide. Lancet 335, 808–811.PubMedCrossRefGoogle Scholar
  24. 24.
    Goodarzr, G, Watabe, M, and Watabe, K (1992) Organ dtstribution and stabihty of phosphorothioated ollgodeoxynucleotides in mice. Biopharm Drug Dispos 13, 22l–227Google Scholar
  25. 25.
    Inagakr, M, Togawa, K., Carr, B.I., Ghosh, K., and Cohen, J S (1992) Antrsense oligonucleotides inhibition of liver cell prohferation and in vivo disposition Transplant Proc 24, 2971–2972Google Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 1996

Authors and Affiliations

  • Leonard M. Neckers
    • 1
  • Daniel Geselowitz
    • 1
  • Christine Chavany
    • 1
  • Luke Whitesell
    • 1
  • Raymond Bergan
    • 1
  1. 1.Clinical Pharmacology BranchNational Cancer InstituteBethesda

Personalised recommendations